NCT02482077 - Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients | Biotech Hunter

Enrollment

112

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

March 15, 2018

Conditions

Chronic Hepatitis C Infection

Interventions

DRUG

SOF+RBV

Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).

DRUG

SOF+DCV

Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60mg tablet administered once daily.

DRUG

LDV/SOF

Ledipasvir 90 mg /Sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily

Trial Locations (2)

100039

Liver Fibrosis Diagnosis and Treatment Centre, 302 Hospital, Beijing

00852

Humanity and Health GI and Liver Centre, Hong Kong

All Listed Sponsors

collaborator

Beijing 302 Hospital

OTHER

lead

Humanity and Health Research Centre

OTHER